Previous 10 | Next 10 |
Acquisition enhances ICON’s patient access in Europe and Africa ICON plc , (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it has acquired a m...
The following slide deck was published by ICON Public Limited Company in conjunction with their 2019 Q1 earnings Read more ...
ICON Wins Multiple Awards at the 2019 Clinical and Research Excellence Awards ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it has been awar...
Increasing visibility of potential study participants to sites and sponsors ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced the release of its...
ICON Public Limited Company (ICLR) Q1 2019 Earnings Conference Call May 02, 2019 10:00 AM ET Company Participants Jonathan Curtain – Vice President of Corporate Finance & Investor Relation Brendan Brennan – Chief Financial Officer Steve Cutler – Chief Ex...
Icon (NASDAQ: ICLR ): Q1 GAAP EPS of $1.63 beats by $0.03 . More news on: ICON Public Limited Company, Earnings news and commentary, Healthcare stocks news, Read more ...
Highlights Net business wins (including pass-through) in the quarter of $885 million; a book to bill of 1.31. Closing backlog (including pass-through) of $7.9 billion, a year on year increase of 10.5%. Quarter 1 reported revenue of $675 million. This represents a year on year ...
Gainers: WHR +8.0% . CDNS +5.4% . NEW +4.3% . CMRE +3.9% . GGB +2.6% . More news on: Whirlpool Corporation, Cadence Design Systems, Inc., Puxin Limited, Stocks on the move, Read more ...
ICON recognised for specialised services offering across product development lifecycle ICON plc, (NASDAQ: ICLR) a global provider of drug development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, has won awards across several ca...
News, Short Squeeze, Breakout and More Instantly...
Highlights Net business wins in the quarter of $2,579 million, an increase of 6.6% on quarter two 2023. Reflects a net book to bill in the quarter of 1.22, and a trailing twelve month net book to bill of 1.24. Closing backlog of $23.8 billion, an increase of 2.0% on quarter one 20...
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 23, 2024 were duly passed by shareholders. ICON also confirmed that following the conclus...
ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2024 with a number of leading business and industry awards recognising the company’s leadership position in the clinical research industry, in addi...